{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:57:06Z","timestamp":1792796226108,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI125362"],"award-info":[{"award-number":["R01AI125362"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1107194"],"award-info":[{"award-number":["OPP1107194"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bmcl.2023.129328","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:59:45Z","timestamp":1684198785000},"page":"129328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition"],"prefix":"10.1016","volume":"90","author":[{"given":"Seungheon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-3827","authenticated-orcid":false,"given":"Melissa S.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkumar","family":"Modukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-7982","authenticated-orcid":false,"given":"Arnab K.","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann P.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Case W.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan R.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Hedstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-4748","authenticated-orcid":false,"given":"Gregory D.","family":"Cuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium","volume":"15","author":"Checkley","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"10.1016\/j.bmcl.2023.129328_b0010","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.3390\/ijerph17186824","article-title":"Cryptosporidium and Cryptosporidiosis: The Perspective from the Gulf Countries","volume":"17","author":"Ahmed","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"1\u20132","key":"10.1016\/j.bmcl.2023.129328_b0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vetpar.2004.09.004","article-title":"Cryptosporidium: a water-borne zoonotic parasite","volume":"126","author":"Fayer","year":"2004","journal-title":"Vet Parasitol"},{"issue":"2","key":"10.1016\/j.bmcl.2023.129328_b0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s40588-021-00159-7","article-title":"Cryptosporidium: Host-Parasite Interactions and Pathogenesis","volume":"8","author":"Pinto","year":"2021","journal-title":"Curr Clin Microbiol Rep"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13567-017-0447-0","article-title":"Bovine cryptosporidiosis: impact, host-parasite interaction and control strategies","volume":"48","author":"Thomson","year":"2017","journal-title":"Vet Res"},{"key":"10.1016\/j.bmcl.2023.129328_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2334-9-195","article-title":"High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial","volume":"9","author":"Amadi","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"9343","key":"10.1016\/j.bmcl.2023.129328_b0035","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bmcl.2023.129328_b0040","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/AAC.42.8.1959","article-title":"Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models","volume":"42","author":"Theodos","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0045","doi-asserted-by":"crossref","first-page":"e0156021","DOI":"10.1128\/AAC.01560-21","article-title":"Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis","volume":"66","author":"Zhang","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.bmcl.2023.129328_b0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/ciaa421","article-title":"Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a Trial","volume":"73","author":"Iroh Tam","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13063-018-2846-6","article-title":"Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial","volume":"19","author":"Nachipo","year":"2018","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.bmcl.2023.129328_b0060","doi-asserted-by":"crossref","first-page":"e0005373","DOI":"10.1371\/journal.pntd.0005373","article-title":"A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis","volume":"11","author":"Love","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmcl.2023.129328_b0065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129328_b0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting plasmodium PI(4)K to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bmcl.2023.129328_b0075","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/infdis\/jix120","article-title":"Bumped-kinase inhibitors for cryptosporidiosis therapy","volume":"215","author":"Hulverson","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.bmcl.2023.129328_b0080","doi-asserted-by":"crossref","first-page":"e00020","DOI":"10.1128\/AAC.00020-17","article-title":"5-aminopyrazole-4-carboxamide-based compounds prevent the growth of cryptosporidium parvum","volume":"61","author":"Huang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jix247","article-title":"Necessity of bumped kinase inhibitor gastrointestinal exposure in treating cryptosporidium infection","volume":"216","author":"Arnold","year":"2017","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.bmcl.2023.129328_b0090","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/infdis\/jiw488","article-title":"Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis","volume":"214","author":"Schaefer","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00436-014-4228-7","article-title":"A novel CDPK1 inhibitor\u2013a potential treatment for cryptosporidiosis in calves?","volume":"114","author":"Lendner","year":"2015","journal-title":"Parasitol Res"},{"issue":"8","key":"10.1016\/j.bmcl.2023.129328_b0100","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/infdis\/jit327","article-title":"A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis","volume":"208","author":"Castellanos-Gonzalez","year":"2013","journal-title":"J Infect Dis"},{"issue":"16","key":"10.1016\/j.bmcl.2023.129328_b0105","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1016\/j.bmcl.2012.06.050","article-title":"Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1","volume":"22","author":"Zhang","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.bmcl.2023.129328_b0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/ml100096t","article-title":"Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii","volume":"1","author":"Murphy","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"12","key":"10.1016\/j.bmcl.2023.129328_b0115","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1128\/IAI.72.12.6806-6816.2004","article-title":"Apical organelle discharge by Cryptosporidium parvum is temperature, cytoskeleton, and intracellular calcium dependent and required for host cell invasion","volume":"72","author":"Chen","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.bmcl.2023.129328_b0120","doi-asserted-by":"crossref","first-page":"eaba8412","DOI":"10.1126\/scitranslmed.aba8412","article-title":"Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase","volume":"12","author":"Vinayak","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.bmcl.2023.129328_b0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.35.2.283","article-title":"Efficacy of halofuginone lactate against Cryptosporidium parvum in calves","volume":"35","author":"Villacorta","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.bmcl.2023.129328_b0130","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1128\/AAC.00873-16","article-title":"Cryptosporidium and toxoplasma parasites are inhibited by a benzoxaborole targeting leucyl-tRNA Synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.bmcl.2023.129328_b0135","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.str.2017.07.015","article-title":"Targeting Prolyl-tRNA synthetase to accelerate drug discovery against malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis, and coccidiosis","volume":"25","author":"Jain","year":"2017","journal-title":"Structure"},{"issue":"4","key":"10.1016\/j.bmcl.2023.129328_b0140","doi-asserted-by":"crossref","first-page":"e02061","DOI":"10.1128\/AAC.02061-18","article-title":"Optimization of methionyl tRNA-synthetase inhibitors for treatment of cryptosporidium infection","volume":"63","author":"Buckner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"10.1016\/j.bmcl.2023.129328_b0145","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baragana","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bmcl.2023.129328_b0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acsmedchemlett.5b00001","article-title":"Discovery of clinical candidate BMS-906024: a potent pan-notch inhibitor for the treatment of leukemia and solid tumors","volume":"6","author":"Gavai","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129328_b0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/19077","article-title":"Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity","volume":"398","author":"Wolfe","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2023.129328_b0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/156802608783334024","article-title":"Gamma-secretase: structure, function, and modulation for Alzheimer's disease","volume":"8","author":"Wolfe","year":"2008","journal-title":"Curr Top Med Chem"},{"issue":"19","key":"10.1016\/j.bmcl.2023.129328_b0165","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1073\/pnas.1506242112","article-title":"Structural basis of human gamma-secretase assembly","volume":"112","author":"Sun","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2023.129328_b0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fnagi.2014.00342","article-title":"Complex regulation of gamma-secretase: from obligatory to modulatory subunits","volume":"6","author":"Gertsik","year":"2015","journal-title":"Front Aging Neurosci"},{"issue":"19","key":"10.1016\/j.bmcl.2023.129328_b0175","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/bi400377p","article-title":"Development and mechanism of gamma-secretase modulators for Alzheimer's disease","volume":"52","author":"Crump","year":"2013","journal-title":"Biochemistry"},{"issue":"42","key":"10.1016\/j.bmcl.2023.129328_b0180","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.bmcl.2023.129328_b0185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0040-4039(00)95771-X","article-title":"A New Amine Resolution Method and Its Application to 3-Aminobenzodiazepines","volume":"28","author":"Rittle","year":"1987","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2023.129328_b0190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1055\/s-1980-29169","article-title":"The Synthesis of 2-Aminobenzophenones","volume":"9","author":"Walsh","year":"1980","journal-title":"Synthesis"},{"issue":"11","key":"10.1016\/j.bmcl.2023.129328_b0195","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1021\/jm031115r","article-title":"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists","volume":"47","author":"Bolli","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129328_b0200","unstructured":"Davis M. Bisfluoroalkyl-1,4-Benzodiazepinone compounds for treating Notch-activated breast cancer. WO2020232191A1, 2020."},{"issue":"15","key":"10.1016\/j.bmcl.2023.129328_b0205","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1055\/s-0035-1561636","article-title":"A practical approach for enantio- and diastereocontrol in the synthesis of 2,3-disubstituted succinic acid esters: synthesis of the pan-notch inhibitor BMS-906024","volume":"27","author":"Quesnelle","year":"2016","journal-title":"Synlett"},{"issue":"9","key":"10.1016\/j.bmcl.2023.129328_b0210","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3390\/microorganisms10091822","article-title":"The effect of short-chain fatty acids on growth of cryptosporidium parvum in vitro","volume":"10","author":"Keelaghan","year":"2022","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/j.bmcl.2023.129328_b0215","doi-asserted-by":"crossref","first-page":"e54072","DOI":"10.1371\/journal.pone.0054072","article-title":"OpenCFU, a new free and open-source software to count cell colonies and other circular objects","volume":"8","author":"Geissmann","year":"2013","journal-title":"PLoS One"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:48:52Z","timestamp":1760773732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"alternative-id":["S0960894X23002068"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129328","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129328"}}